Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Dow
Mallinckrodt
AstraZeneca
Moodys

Last Updated: January 29, 2022

DrugPatentWatch Database Preview

Claims for Patent: 5,650,389

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 5,650,389
Title: Methods for the inhibition of complement activation
Abstract:Decorin, a small collagen-binding dermatan sulfate proteoglycan, is widely distributed as a component of extracellular matrices. Using a solid phase binding assay, the inventors demonstrated that decorin bound C1q at physiologic pH and ionic strength. The interaction did not require divalent cations and was time and temperature dependent reaching equilibrium in 4 hours at 37.degree. C. Binding was specific and saturable with an apparent dissociation constant of 7.6.times.10.sup.-9 M. Decorin was shown to bind pepsin-derived fragments containing the collagenous domain of C1q and collagenase-derived fragments containing the globular domain of C1q. Since these fragments share a short sequence of amino acids, this finding suggests that decorin binds to a region of C1q located near the junction of the two domains. Competition studies using purified preparations of the decorin core protein and the glycosaminoglycan chains showed that only the former inhibited binding of decorin to C1q indicating that the interaction is mediated by the decorin core protein. Decorin was shown to inhibit the hemolytic activity of purified C1 as well as C1 in normal human serum. Approximately 50% inhibition was observed at a decorin concentration of 2 .mu.g/ml. Inhibition was not observed if C1 was bound to antigen-complexed antibody. Furthermore, neither the core protein, nor the glycosaminoglycan chain of decorin inhibited C1 indicating that the intact proteoglycan is necessary for functional activity. These studies therefore demonstrate the usefulness of decorin and related proteoglycans in suppression of complement activation of the immune system.
Inventor(s): Krumdieck; Richard (Birmingham, AL), Hook; Magnus A. O. (Houston, TX), Volanakis; John E. (Birmingham, AL)
Assignee: University of Alabama at Birmingham Research Foundation (Birmingham, AL)
Application Number:08/025,357
Patent Claims:1. A method for suppressing antibody dependent complement activation in a subject comprising administering to the subject an amount of decorin effective to suppress antibody dependent complement activation in a sterile solution rendered pharmacologically acceptable.

2. A method for inhibiting C1 complex in solution comprising adding to such a solution an amount of decorin that is effective to suppress hemolytic activity of C1.

3. A method for binding decorin to C1q in solution comprising adding to such a solution an amount of decorin that is effective to allow binding of the decorin to the C1q.

4. The method of claim 3, wherein decorin is added as a pharmaceutical composition comprising an effective binding amount of decorin dispersed in an acceptable buffer or stabilizer.

5. The method of claim 4, wherein the pharmaceutical composition is further defined as an aqueous solution comprising from 3 to 7 .mu.g/ml of decorin dispersed in an acceptable buffer or stabilizer.

6. The method of claim 5, wherein the pharmaceutical composition is further defined as comprising an acceptable buffer or stabilizer selected from the group of sterile water, dextrose water, Hank's balanced salt solutions, PBS and Ringer's lactate.

7. The method of claim 3, wherein the decorin is added to the solution to achieve a final concentration of at least about 0.2 to 20 .mu.g/ml.

8. The method of claim 3, wherein the decorin is naturally derived.

9. A method for inhibiting C1 complex activity in solution comprising adding to such a solution an amount of decorin that is effective to suppress hemolytic activity of C1.

10. The method of claim 9, wherein the decorin is added in an amount effective to provide a final concentration of between about 0.2 and about 20 .mu.g/ml.

11. The method of claim 9, wherein decorin is added as a pharmaceutical composition comprising an amount of decorin effective to inhibit C1 complex activity in a sterile solution rendered pharmacologically acceptable.

12. The method of claim 10, wherein the C1 complex is inhibited in human serum at physiological pH.

13. The method of claim 12, wherein the decorin is added in an amount effective to provide a final concentration of between about 0.2 and about 20 .mu.g/ml.

14. A method for reducing the complement activating potential of an implanted medical device comprising coating the implanted medical device with an effective amount of decorin.

15. The method of claim 14, wherein the object comprises medical tubing, a shunt, a catheter or artificial implant.

16. A method for inhibiting C1 complex in a solution having physiological ionic strength, comprising adding to said solution an amount of decorin that is effective to suppress hemolytic activity of C1.

17. The method of claim 16, wherein said decorin is added as a pharmaceutical composition comprising ann amount of decorin effective to suppress hemolytic activity of C1 in a sterile solution rendered pharmacologically acceptable.

18. The method of claim 17, wherein said decorin is added in an amount to achieve a final concentration of between about 0.2 and 20 .mu.g/ml.

19. A method for binding decorin to C1q in a solution of physiological ionic strength, comprising adding to such a solution an amount of decorin that is effective to allow binding of the decorin to the C1q.

20. The method of claim 19, wherein decorin is added as a pharmaceutical composition comprising an effective binding amount of decorin dispersed in an acceptable buffer or stabilizer.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
McKinsey
McKesson
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.